[e-drug] Cheaper MDR-TB drugs

E-DRUG: Cheaper MDR-TB drugs
�------------------------------------------------------
[copied from TB-NET with thanks; NN]

tbnet (00544) PUB: Applying to 'Green Light Committee'
------------------------------------------------------
Instructions for applying to the Green Light Committee for access to
second-line anti-tuberculosis drugs (WHO/CDS/TB/2001.286) is now available
on the WHO website at

http://www.who.int/gtb/policyrd/PDF/GLCApplicationInstructions.pdf

The WHO Working Group on DOTS-Plus for MDR-TB identified access to
second-line anti-TB drugs as one of the major obstacles to the
implementation of DOTS-Plus pilot projects. The Working Group has made
arrangements with the pharmaceutical industry to provide
concessionally-priced second-line anti-TB drugs to DOTS-Plus pilot projects
meeting the standards outlined in the Guidelines for Establishing DOTS-Plus
Pilot Projects for the Management of MDR-TB. It is the task of the Green
Light Committee (http://www.who.int/gtb/policyrd/PDF/DOTSGLC.pdf) to review
applications from potential DOTS-Plus pilot projects and determines whether
or not they are in compliance with the Guidelines for Establishing DOTS-Plus
Pilot Projects for the Management of MDR-TB. Project managers interested in
being reviewed by the Green Light Committee should review the document
'Instructions for Applying to the Green Light Committee for Access to
Second-line Anti-Tuberculosis Drugs' and contact WHO.

In order to ensure timely consideration, the applications for review by the
Green Light Committee must be received by WHO in advance of the
corresponding meeting date. The following table gives meeting dates and
application due dates for 2001.

Meeting Date Application Due Date
27 February 2001 1 February 2001
1 June 2001 4 May 2001
3 September 2001 9 August 2001
3 December 2001 1 November 2001

--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.